Clinical Trial

Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to explore the effects of Vebreltinib in primary glioblastoma patients receiving a combination therapy of chemotherapy (temozolomidel) and MET-TKI.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-13.
Trial Details
NCT Number NCT06780592
Lead Sponsor Huashan Hospital
Collaborators: Beijing Tiantan Hospital, Beijing Sanbo Brain Hospital
Conditions Glioblastoma
Enrollment 60 participants
Start Date 2025-01-13
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-22